Clinical Trial: Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
Study Status: Completed
Recruit Status: RECRUITING
Condition: Recurrent Multiple Myeloma
Study Type: INTERVENTIONAL
Official Title: Phase II Trial for Evaluation of Alternate Doses and Dosing Schedules of Belantamab Mafodotin in Triple-Class Refractory Multiple Myeloma
Brief Summary:
This phase II trial tests alternate doses and dosing schedules of belantamab mafodotin in treating patients with triple-class multiple myeloma that has come back (after a period of improvement) (recurrent) and/or does not respond to treatment (or that has not responded to previous treatment) (refractory).Belantamab mafodotin is a monoclonal antibody, belantamab, linked to a chemotherapy drug, mafodotin.Belantamab is a form of targeted therapy because it attaches to specific molecules (receptors) on the…
Read more